Condition
Dermatomycoses
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
3 treatments under study, led by Ciclopirox
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 4 (1)
Trial Status
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Ciclopirox1
- Lozanoc 50mg1
- Itraconazole1
Active Sponsors
- Ferrer Internacional S.A.1
- Boryung Pharmaceutical Co., Ltd1
Top Investigators
Hospital Reina Sofia, Cordoba, Spain
Department of Clinical Pharmacology and Therapeutics, Asan Medical Center
Related Conditions
- Superficial Mycoses1
- Candidiasis1
- Histoplasmosis1